Clinical Trial Update: Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sorafenib in metastatic or recurrent prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED